NCT07349693: An ongoing trial by Everfront Biotech Co., Ltd.
This trial is ongoing. It must report results 3 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07349693 |
|---|---|
| Title | A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 1, 2026 |
| Completion date | Dec. 1, 2028 |
| Required reporting date | Dec. 1, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 22, 2026 |
| Days late | None |